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Abstract
PET (Positron Emission Tomography) is a nuclear medicine imaging method, frequently used in
oncology during the last years. It is a non-invasive technique that provides quantitative in vivo
assessment of physiological and biological phenomena. PET has found its application in common
practice for the management of various cancers.
Lung cancer is the most common cause of death for cancer in western countries.
This review focuses on radiotracers used for PET scan with particular attention to Non Small Cell
Lung Cancer diagnosis, staging, response to treatment and follow-up
Introduction
PET scan represents one of the most sophisticated nuclear
medicine techniques of the last years. It was initially used
to study the brain and the heart, but today it is used
mainly in oncology. PET scanning is a non-invasive imag-
ing method that differs from others because it observes "in
vivo" metabolic activity using radio-isotopes with specific
tissutal tropism. More in detail PET scans necessitate the
injection of a small quantity of biologically important
material like glucose or oxygen which have labelled with
radio-nuclides such as carbon-11, nitrogen-13, oxygen-15
and fluoride-18.
All the used isotopes are radioactive with a rapid time of
decaying by positron emission: carbon-11 or 11C is a radi-
oactive isotope of carbon with a half-life in the order of
twenty minutes. Nitrogen-13 or 13N is an isotope of
nitrogen with a half life of approximately ten minutes.
Oxygen-15 or 15O is an isotope of oxygen having a half
life of about two minutes.
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18. It is a fluorine isotope with a half life of approximately
110 minutes. This tracer is very useful because of its long
half life and because it decays by emitting positrons hav-
ing the lowest positron energy which contributes to a
high-resolution imaging acquire.
Most articles have considered the utility of FDG (fluorine-
18 combined with deoxy-glucose) which is the most used
radiotracer in clinical practice. Actually, a number of new
compounds with promising prospective for PET imaging
are also available to gain information about specific cellu-
lar and molecular tumour pathways.
In the second part of this review a wide panoramic on the
use of this technique will be conducted regarding an
important oncologic pathology, both in term of incidence
and mortality: lung cancer.
18F-FGD and Alternative tracers to 18F-FDG in oncology 
and other diseases
18F-FDG
FDG is a glucose analogue extensively used in oncology
for staging, restaging and recently for the evaluation of
tumour response to treatment [1]. Cancer cells demon-
strate up regulation of glucose metabolism: uptake of glu-
cose or glucose-analogues, as deoxy-glucose is increased.
Labeling deoxy-glucose with the positron emitting radio-
nuclide 18F to form 18F-FDG renders these cells detecta-
ble using PET. In detail, 18-FDG is transported into the
cells by the same carrier as glucose, but at a much higher
rate. Then it is phosphorylated to FDG-6-phosphate
(FDG-6-P) by the action of hexokinase or glucokinase [2].
This substance does not enter the standard metabolic
pathways because of the presence of fluorine at the C-2
position of the ring instead of the hydroxyl group in glu-
cose and can leave the cell only slowly by the action of
glucose-6-phosphatase. So it is trapped and accumulated
in the neoplastic cells. This 'metabolic trapping' of FDG-
6-P forms the basis of the analysis of PET data. (Fig 1)
The basis for using FDG in oncology was demonstrated by
Warburg who observed an increase in glycolytic activity in
cancer cells, under both aerobic and anaerobic conditions
[3-5]. Moreover neoplastic transformation often deter-
mines an increase in the activity of glycolytic enzymes
(e.g. hexokinase) and in glucose transporters (e.g. GLUT1)
[6]. Cell mass influences this glycolytic activity, while cell
proliferation affects the increase in glucose transport. Oth-
erwise this condition is not specific to malignant tumors;
in fact accumulation of glucose can also be present in
benign pathology and inflammatory disease, where acti-
vated inflammatory cells or macrophages also use glucose
as energy. Clinically inflammatory foci, sarcoidosis, and
active tuberculosis are often shown as FDG positive
lesions [7,8]. On the other hand some malignant cells
such as carcinoid tumors and bronchioalveolar lung carci-
noma are FDG-negative [9]. Moreover in hepatocellular
carcinoma, highly differentiated cancer cells are FDG-neg-
ative and poorly differentiated cancer cells are FDG-posi-
tive; the FDG-positive cells indicate poor prognosis,
reflecting the histological cell type.[10]
Mechanism of Glucose trapping in FDG-PET [98]Figure 1
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tion in some normal tissues, which can result in a low or
decreased tumor to background ratio (Fig 2). In fact, the
normal brain has a high glucose uptake, while in most
brain tumors the uptake of FDG is similar or lower than
in the normal tissue. The excretion of FDG makes urine
extremely radioactive. Although bladder and prostate
tumors are FDG-avid cancers this condition can create
problems in the diagnosis of these neoplasms [11].
While traditional radiological imaging techniques (e.g.
Computed Tomography-CT-scan, Magnetic Resonance
Imaging-MRI) make available structural information and
identify disease states on the basis of cross anatomical
changes, FDG PET imaging provides information on the
biochemical processes which may precede cross anatomic
changes. [12]. The limited spatial resolution of PET due to
a lack of anatomic information can be overcome by com-
bining morphologic CT and functional PET data.
Thus functional scans obtained with FDG PET are not
only complementary to those obtained with conventional
modalities but also may be more sensitive because altera-
tions in tissue metabolism generally anticipate anatomic
alterations.
According to EORTC guidelines for better evaluation of
lesions, PET must be combined with Computed Tomogra-
phy, but response criteria are still not available [13].
To date newer PET/CT protocols have been developed, but
there is no consensus about them or their standardization
[14]. This remains a fundamental objective to better estab-
lish the efficacy of PET/CT for specific clinical application.
In fact, high quality contrast enhanced CT scans, obtained
in parallel with PET images, can contribute to diagnosis,
anatomic correlation and attenuation correction of PET
scans.
To correctly determine FDG PET activity it has been intro-
duced the Maximum Standardized Uptake Value (SUV
max). It is defined as maximum tumour concentration of
FDG divided by the injected dose, corrected for the body
weight of the patient: (SUV max = maximum activity con-
centration [injected dose/body weight]). It represents the
metabolic activity for the tumor compared with that in
surrounding tissue, corrected for injected dose and patient
weight.
18F-Fluoro-L-dihydrophenylamine
Among the newest studied tracers there is18 F-Fluoro-L-
dihydroxyphenylamine (18F-fluoro-L-DOPA). It is used to
evaluate the in vivo activity of aromatic l-amino acid
decarboxylase of dopaminergic system. For these charac-
teristics this compound has been used in clinical practice
for parkinsonisms diagnosis and to investigate subclinical
lesions of the substantia nigra in Parkinson disease related
disorders.[15] Moreover it has been recently found appli-
cation for detection of neuroendocrine tumours (NETs),
that are capable to accumulate and decarboxylate amine
precursors resulting in a high uptake in PET scans with18F-
fluoro-L-DOPA [1].
Somatostatin tracers
Somatostatin based radiotracers (analogues of somatosta-
tin labelled with radioisotopes) are useful for diagnosis in
patients with cancers (Neuroendocrine Tumours-NETs)
which express the somatostatin receptor 2 (SSTR2). They
are able to orient treatment on the basis of the quality and
quantity of tracer uptake. In Fact well differentiated NET
tumours do not necessarily shown an increased glucose
metabolism, while they can be treated with new target
drugs (Sunitinib) in addition to somatostatin analogues.
On the other hand poor differentiated NETs and with
Normal PET imagingFigure 2
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cytotoxic drugs. [16,17]
11C-Choline
Choline is a precursor of biosynthesis of an essential ele-
ment of phospholipids of the cell membrane (phosphati-
dil – choline). In neoplastic tissue there is an elevated
level of phosphatidil-choline and an up-regulation of the
enzyme that catalyzes the phosphorilation of choline
[18,19].
Thus a new PET radiotracer (11C-Choline) has been devel-
oped and is useful mostly to detect well differentiated
tumours with low glucose uptake [20,21]. In clinical
research PET choline is mostly studied in prostate cancer,
also because of the low sensitivity and specificity of 18F-
FDG. In particular the usefulness of this test is related
principally to the detection of local tumour recurrence
after radical prostatectomy or distant metastatic disease
[22] or to assess the response to hormonal therapy in
patients with androgen-dependent tumours or chemo-
therapy for patients with androgen – independent
tumours [23].
18F-16β-Fluoro-5-dihydrotestosterone
18F-16 β-Fluoro-5α-dyhidrotestosterone (FDHT), a struc-
tural analogue of 5-α-dyhidrotestosterone, can be useful
to detect metastatic and recurrent prostate cancer lesions,
binding affinity and selectivity for androgen receptors
(ARs) [24].
18F-FLT
18F-3-Fluoro-3-deoxy-thymidine (18-F-FLT) is a pyrimi-
dine analogue that reveals the activities of thymidine-
kinase-1 during the phase S of mitoses [25]. First it was
considered a promising radiotracer for its biological char-
acteristics, but several studies have analyzed the role of
this molecule in different tumors showing a lower uptake
of 18-F-FLT than 18-F-FDG, with the exception of brain
tumors. [26-29]
11C-Acetate
11C-Acetate is a metabolic substrate for synthesis of cho-
lesterol and lipids. [30] This compound has not a renal
clearance and initially was considered to be able to play
an important role for imaging of prostate and kidney
tumors. Following studies did not confirm the primitive
hypothesis showing that acetate accumulation in renal
cell carcinoma was lower or similar to normal kidney
parenchyma, [31] while it remains promising in prostate
cancer and hepatocellular carcinoma. [32-34]
18F-Fluoride. 11C-Methionine
Fluorine-18-Fluoride is a PET tracer with elevated utility
for detection of bone metastases in various tumors
[35,36]. In fact fluoride ion is switched with hydroxyl
group in the bone crystals forming fluoroapatite: where
the turnover is greatest there are high deposits. An
increased 18F-Fluoride PET uptake in bone lesions reveals
both an increased bone turnover and blood flow.
Another studied tracer is represented by 11C-Methionine.
Methionine is an important amino acid for protein syn-
thesis process. The role of this tracer has been evaluated in
various trials, mostly in brain tumors [37]. because it does
not accumulate in normal brain tissue while FDG can not
be valuable for the high glucose activity of normal brain.
Other studied fields of application of 11C-Methionine
have been head and neck squamous cell carcinoma
(HNSCC) and prostate cancer, with minor oncological
relevance [38,39].
Utility of FDG PET in NSCLC
Non Small Cell Lung Cancer
Lung Cancer is one of the most important causes of
tumour-related deaths in industrialized countries. NSCLC
treatment includes surgery, radiation therapy, chemother-
apy and molecular therapy. The choice of treatment alone
or in combination is based on clinical and pathological
tumour stage.
PET scan plays an important role for tumour diagnosis
and staging, providing functional information simultane-
ous to anatomical details when PET is combined with
computed tomography (CT)
Initial Staging
The mainly point to establish a correct staging of NSCLC
is to identify patients candidates to surgery versus those
ones who are inoperable but can obtain benefits from
chemotherapy, radiotherapy or both.
In detail, patients with N0 – N1 disease (no metastatic
lymph nodes or only intrapulmonary/hilar nodes) are
generally candidates for surgical resection. On the con-
trary patients with N2 disease (ipsilateral mediastinal
lymph nodes metastases) could gain benefit from a com-
bination of local and systemic treatments. Patients with
N3 disease (contra lateral mediastinal lymph nodes
metastases) are considered for non operability. [40]
Thus, an accurate loco regional lymph nodes assessment
is mandatory to choose the best treatment options. This
could be done either with invasive techniques (first of all
mediastinoscopy) or with non-invasive exams such as CT
or FDG PET.
Among the invasive techniques, endobronchial ultra-
sound guided-fine needle aspiration (EUS-FNA) deserves
a particular discussion. This new technique is now inPage 4 of 10
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sibility and specificity comparable to mediastinoscopy for
staging malignant nodes in NSCLC [41]. In a recent meta-
analysis Micames et al., analyzing 18 eligible studies, in
order to estimate the diagnostic accuracy of EUS-FNA for
staging mediastinal lymph nodes (N2/N3 disease) in
patients with lung cancer, have concluded that EUS-FNA
is a safe modality for the invasive staging of lung cancer.
Moreover it is highly sensitive when used to confirm
metastasis to mediastinal lymph nodes seen on CT scans
and has the potential to prevent unnecessary surgery in a
large proportion of cases [42].
On the other hand it has been shown the relative fre-
quency of metastatic N2 disease in the posterior mediasti-
nal lymph nodes which are not accessible via
mediastinoscopy but are easily and accurately sampled by
EUS-FNA [43]. Thus some argue that both mediastinos-
copy and EUS-FNA should be performed routinely in all
patients prior to resection.[44]
The increasing availability of FGD PET offers a noninva-
sive, accurate alternative for staging the mediastinum.
Whether or not FDG-PET should be used as a routine pro-
cedure in mediastinal lymph node staging, replacing
mediastinoscopy, is still a matter of debate [45].
American College of Chest Physicians guidelines [46] rec-
ommend FDG PET for non invasive staging due to the low
sensitivity and specificity of the commonly used CT in the
identification of node involvement. A large number of
studies on PET accuracy, varying in quality and design,
have evaluated its role in mediastinal lymph nodes stag-
ing using surgery (mediastinoscopy and/or thoracotomy
with mediastinal lymph node dissection) as the gold
standard of comparison [47-56]. They have been previ-
ously summarized in six meta-analyses (Tab 1) and con-
vincingly demonstrated that PET is an imaging technique,
superior to CT, for mediastinal lymph node staging terms
of accuracy [57-62]. In fact CT scanning is mainly a mor-
phologic imaging test; size or shape of lymph node are the
most important CT criteria for tumour involvement but
they are limited by low sensitivity and specificity [63].
On the one hand, of major clinical importance is the high
negative predictive value of mediastinal FDG-PET (up to
97%)[47,64,65]. In Patients with mediastinal PET-nega-
tive results mediastinoscopy may be redundant and stag-
ing may be adequate without invasive procedure,
proceeding directly to thoracotomy [18]. This led to the
recommendation to omit mediastinoscopy in case of a
negative mediastinal FDG-PET[64,66,67]
On the other hand, some conditions must be respected:
sufficient FDG uptake in the primary tumor; use of a ded-
icated PET camera; absence of a central tumor or impor-
tant hilar lymph node disease that may led to under-stage,
obscuring coexisting N2 disease on PET [68,55,69]. Addi-
tionally, centrally located disease are also associated with
a higher incidence of occult N2 disease than non-centrally
located tumors [70].
Previous studies have reported that PET positive uptake in
a hilar node is a risk factor for occult N2 disease
[43,27,70]. In fact FDG-positive hilar nodes are predictive
for microscopically (from a few cells to a few millimetres)
involvement in mediastinal nodes. No other currently
available imaging technique can detect such small volume
disease.
As reported by Verhagen, FDG-PET reduces the number of
mandatory mediastinoscopy procedures by 46% with no
increase in unexpected N2 involvement at thoracotomy
[27]. Even if PET seems superior in staging N2 disease, it
is still unable to carefully differentiate N1 from N2
involvement. Notably, limits of PET consist of failure to
show anatomic landmark and imperfect spatial resolu-
tion. These aspects could restrict its use to assess loco
regional lymph node metastases [71,72]. The use of inte-
grated PET-CT could attenuate this limit, improving ana-
tomic localization of positive lymph nodes [73]. This
could enable a better distinction between central tumours
and contiguous lymph nodes (e.g. central tumour alone
or central tumour with N2-disease), or between adjacent
lymph node stations (e.g. hilar N1- or mediastinal N2-dis-
ease). Thus the simultaneous use of these two imaging
exams may obtain greater staging accuracy than either test
Table 1: Meta-analyses of mediastinal lymph node staging
Author Sensitivity Specificity PPV NPV N Studies N Pts
Fischer MB et al [57] 0,83 0.96 0,87 0,95 17 nr
Toloza EM et al [58] 0,84 0,89 0,79 0,93 18 1045
Helwing D et al [60] 0,88 0,92 nr Nr 20 1292
Dwamena BA et al. [59] 0,79 0,91 0,9 0,93 16 639
Gould MK et al [61] 0,85 0,90 nr Nr 32 1959
Birim O. et al [62] 0,83 0,92 nr Nr 17 833
PPV: positive predictive value; NPV: Negative predictive value; Pts: Patients; nr: Not reportedPage 5 of 10
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tial staging of lung cancer.[74]
In a cost-effectiveness analysis on use of PET for all N0
patients at CT scan, the results were encouraging. In fact
the cost of PET scanning was almost counterbalanced by
the more appropriate selection of patients for beneficial
surgery [75].
On the contrary, the use of cervical mediastinoscopy non-
selectively among stage 1 NSCLC has been reported to be
not cost-effective [76] as the incidence of N2 disease is less
than 3% [43].
Thus, on this latter prospective trial, Cerfolio et al suggest
to reserve mediastinoscopy to only those patients with
clinically staged N0 disease with a right upper lobe lesion
(in which they found 10.4% positive rate for mediastinos-
copy), and to limit EUS-FNA in patients staged N0 with
tumors only in the right lower lobe (in which they found
15.4% positive rate for EUS-FNA). Moreover the authors
recommend both mediastinoscopy and EUS-FNA in
patients clinically staged as N1 after integrated PET/CT.
However, as described in a recent study by Al-Sarraf et al.
[70] 16% of patients with negative uptake in mediasti-
num on integrated PET-CT had occult N2 disease follow-
ing resection.
Other pathological factors such as tumor subtype, grade
of differentiation, tumor size, T stage and SUV max of pri-
mary tumor tend to be associated with the biological
aggressiveness of tumors [77] and are of prognostic signif-
icance rather than being predictors of occult metastases in
mediastinal nodes [70].
In another study by Lee et al the maximum standardized
uptake value is a predictor of individual lymph node
metastasis in non-small cell lung cancer. Using SUVmax of
5.3 to assign malignanc, y highly improve PET/CT accu-
racy, thus significantly reducing the number of false posi-
tive results. The authors conclude that in the absence of
other indications for mediastinoscopy, (N1 disease, cen-
tral or multiple tumors), mediastinoscopy can be omitted
in patients who have a maxi-SUV of less than 5.3 in their
N2 lymph nodes and low max-SUV primary tumor to
mediastinal lymph node ratio, as found by integrated
PET/CT analysis. [78]
Albeit the positive predictive value is plausible, it must
not be forgotten that false positive results can be obtained
in the case of anthracosilicosis, infection, or granuloma-
tous disorders [26]. In these patients mediastinoscopy in
mandatory to confirm N2 or N3 disease in order to ensure
that patients with resectable N0 or N1 disease can gain the
possibility of resolutive surgery.
Kuehl et al. have described a well defined PET/CT staging
protocol. According to the authors the procedure should
include the analysis of the chest and abdomen in order to
stage locally and to detect distant metastases. Moreover
the field should include the neck to detect supraclavicular
lymph nodes involvement. [79]
However, the general recommendation is that if PET scan
result is negative, invasive mediastionoscopy could be
avoided; on the contrary, a positive PET scan, makes
mediastinoscopy necessary for lymph node sampling
because of possibility of false-positive PET scan [46].
Regarding the distant metastases detection, a recent rand-
omized trial [55] suggests that the addition of PET scan-
ning to a conventional workup identified more
asymptomatic patients with distant metastases among
those with suspected NSCLC. Moreover in several studies
[52,64]. FDG-PET scan improved clinical staging of lung
cancer patients. Unexpected extra thoracic metastases
were detected by FDG-PET in 15% of patients without evi-
dence of metastases after conventional staging. This could
avoid futile mediastinoscopy and eventually thoracot-
omy.
Treatment
The use of PET can be applicable for selection or delinea-
tion of radiotherapy target volumes. In particular PET
with 18F-FDG has taken on increasing importance for
radiotherapy planning purposes. In fact because of the
hight sensitivity of FDG PET for the staging of lymph node
metastases in lung cancer implies that a negative PET
examination could permit focusing on the primary neo-
plasm reducing target volumes [80].
Few studies have prospectively evaluated PET with 18
FDG in radiotherapy planning in term of its role of local
control and survival. It has been reported that PET based
mediastinal lymph nodes radiotherapy does not affect the
local control reducing the target volume. [81]
Omitting elective nodal irradiation of clinically unin-
volved nodal station is a way of reducing toxicity in non
small cell lung cancer. [81] This modality could be suc-
cessfully applied also for patients with limited disease
small cell lung cancer (LD-SCLC) for whom the treatment
of choice is concurrent chemo-radiotherapy. [82]
In particular in a study conducted on for 21 patients with
N2/N3 NSCLC by van Der Wel et al. the use of PET/CT to
define the radiotherapy target volume, demonstrated anPage 6 of 10
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ated with a reduction of esophagus and lung toxicity. [83]
Response to Therapy
For assessing treatment with chemotherapy or radiother-
apy in patients with non small cell lung cancer, PET and
PET/CT play a major role than CT alone due to the fact
that metabolism is a more sensitive marker for response to
therapy than morphology. [84]
In patients undergoing therapy, imaging can play a crucial
role and may aid in predicting the outcome of treatment
regimens [85]. After radiotherapy, anatomic imaging
alone has limited utility: fibrosis, atelecttasis or inflamma-
tory infiltration related to radiation pneumonitis could
hide residual tumour, thus tumour can be differentiated
from scarring by using FDG PET [86]. CT has been shown
to be suboptimal in restaging the mediastinum after ther-
apy [87-89]. FDG PET is more sensitive than and as spe-
cific as traditional imaging to assess for residual disease or
recurrence after intervention [90].
Dooms et al. in a very recent study evaluated the role of
FDG PET in a particular subset of patients. This popula-
tion was represented by resectable stage IIIA-N2 non small
cell lung cancer subjects for whom therapy is often induc-
tion chemotherapy followed by resection. The authors
concluded that FDG PET should select patients, after
induction chemotherapy, who can be considered for sur-
gical treatment [91]. In fact in a precedent study con-
ducted by Rohren et al. were compared patients in which
there were a residual FDG uptake after treatment with
those ones without FDG uptake, with a poor prognosis in
the first ones.[87]
Despite the results of the various treatments it needs to
consider that the radiotherapy could be responsible of
inflammatory reactions that could give false positive to
FDG PET examination. For this reason, to have a real eval-
uation of the response to the treatment is necessary to
attend some weeks after chemotherapy administration
and several months after radiotherapy [92].
Follow-Up
The clinically efficacy of the follow-up of lung cancer and
the treatment of recurrence are the subject of contro-
versy[93]. Relapsing lung cancer might be considered as a
poor prognostic factor and its diagnosis could have no
therapeutic impact. On the other hand, local recurrence
could be object of re-treatment with acceptable long term
survival. In fact several studies have demonstrated that re-
treatment after surgery may increase survival. Surgery as a
second curative intent needs early diagnosis of relapse and
appropriate selection of patients [94].
Thus another possible application of PET/CT is evaluation
of patients with the suspect of recurrence during the fol-
low-up. This is supported by clinical advantage to detect
not only local relapse but also distant metastatic spread-
ing, with a significant impact on patient's management
and selection. [95]
When considering suspected recurrences, it has been
reported that PET may have a major impact on treatment.
In one study, PET affected 63% of patients with possible
relapse [96].
In a recent study by Hellwig et al.[97] the authors state
that FDG-PET accurately detects recurrent lung cancer,
while the detection of unsuspected distant metastases
avoids unnecessary treatments. They also affirm that SUV
is an independent prognostic factor and that PET could
help in the selection of patients who will benefit from sur-
gical re-treatment.
Hence, also in this field, fusion technology, gaining ana-
tomical and physiologic data will give useful information,
supporting the correct management of these patients.
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